Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05538546
Other study ID # OASIS-CHESS
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 2022
Est. completion date December 2023

Study information

Verified date September 2022
Source Huashan Hospital
Contact Qiran Zhang
Phone +8618800245704
Email qrzhang12@fudan.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count >150,000 are considered to have very low risk of having varices requiring treatment, but whether these patients can be followed up by repetition of this criteria lacks sufficient evidence. This study aimed to assess the value of Baveno VI criteria for following up and monitoring of varices needing treatment in patients with compensated cirrhosis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1000
Est. completion date December 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Patients with liver cirrhosis diagnosed according to clinical or pathological criteria; 2. No decompensation events in the past, no ascites shown by ultrasound, no significant abnormality in liver function and coagulation function; 3. Willing to carry out routine diagnosis and treatment evaluation and follow-up liver stiffness test and gastroscopy; 4. Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count >150,000) at baseline, or patients don't meet Baveno VI criteria (with a liver stiffness = 20kPa or with a platelet count =150,000) at baseline, but don't have varices requiring treatment (proved by endoscopy). 5. Voluntarily signed the informed consent. Exclusion Criteria: 1. Patients with liver carcinoma; 2. Patients with portal vein thrombosis; 3. Patients with varices requiring treatment confirmed by gastroscopy during the screening period; 4. Patients who have received propranolol, ligation, sclerosis, splenectomy, transcatheter splenic arterial embolization, transjugular interhepatic portosystemicstent-shunt and other treatments to decrease portal hypertension in the past.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Complete blood count
Complete blood count will be conducted at 12th month and 24th month from baseline.
Transient elastrography
Transient elastrography, and endoscopy will be conducted at 12th month and 24th month from baseline.
Endoscopy
Endoscopy will be conducted at 12th month and 24th month from baseline.

Locations

Country Name City State
n/a

Sponsors (21)

Lead Sponsor Collaborator
Huashan Hospital Beilun Hospital of Chinese Medicine, Fifth Hospital of Shijiazhuang City, First Affiliated Hospital of Fujian Medical University, Gansu Wuwei Tumor Hospital, Liuzhou Workers Hospital, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Shenzhen Third People's Hospital, Taizhou People's Hospital, The Affiliated Hospital of Xuzhou Medical University, The Fifth People's Hospital of Wuxi Affiliated Hospital of Jiangnan University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Xian Jiaotong University, The First People's Hospital of Taicang, The Fourth People's Hospital of Qinghai Province, The Sixth Hospital of Dalian, The Sixth Hospital of Qingdao, The Third Affiliated Hospital of Hebei Medical University, The Third People's Hospital of Linfen City, The Third People's Hospital of Taiyuan, Xinjiang Hospital of Chinese Medicine

Outcome

Type Measure Description Time frame Safety issue
Primary The missing rate of Baveno criteria at 12th month follow-up visit The number of patients with varices requiring treatment under endoscopy divided by the number of patients meet Baveno criteria at 12th month follow-up visit 12 months from baseline
Secondary The missing rate of Baveno criteria at 24th month follow-up visit The number of patients with varices requiring treatment under endoscopy divided by the number of patients meet Baveno criteria at 24th month follow-up visit 24 months from baseline
Secondary Cumulative rate of decompensation events The cumulative rate of decompensated events in all participants during the 24 months. 24 months from baseline
Secondary Cumulative rate of gastrointestinal bleeding The cumulative rate of gastrointestinal bleeding in all participants during the 24 months. 24 months from baseline
Secondary Cumulative rate of 6-week death post gastrointestinal bleeding The cumulative rate of death in 6 weeks post gastrointestinal bleeding in patients with gastrointestinal bleeding events during the 24 months. 24 months from baseline
See also
  Status Clinical Trial Phase
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05014594 - Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT Phase 2
Not yet recruiting NCT03631147 - The Effect of Rifaximin on Portal Vein Thrombosis N/A
Completed NCT04939350 - Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
Completed NCT02528760 - To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis N/A
Recruiting NCT05484206 - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Phase 1
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Recruiting NCT02983968 - Use of the French Healthcare Insurance Database
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT02596880 - Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics Phase 3
Completed NCT02247414 - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Phase 4
Withdrawn NCT01956864 - Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer Phase 1
Completed NCT02016196 - Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS Phase 3
Completed NCT01447537 - Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis N/A
Completed NCT01362855 - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Completed NCT02113631 - Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir N/A
Active, not recruiting NCT01205074 - ¹³C-Methacetin Breath Test (MBT) Methodology Study Phase 2/Phase 3
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01231828 - Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. N/A
Terminated NCT00375011 - Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics